来自官方财务报表的收入、利润与现金流历史。
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.
| 利润表 | TTM → 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $14.6B | $14.0B | $13.0B | $12.2B | $11.9B | $13.1B | $14.0B | $11.6B | $11.3B | $10.4B | $9.6B | $8.7B | $6.0B | $5.8B | $5.7B | $5.5B | $5.0B | $4.7B | $4.5B | $4.1B | $3.6B |
| 毛利 | $4.1B | $3.7B | $3.6B | $3.4B | $3.7B | $5.0B | $5.0B | $3.3B | $3.2B | $3.5B | $3.2B | $2.9B | $2.2B | $2.2B | $2.2B | $2.3B | $2.1B | $2.0B | $1.9B | $1.7B | $1.5B |
| 毛利率% | 28.0% | 26.8% | 27.9% | 27.7% | 31.3% | 38.0% | 35.4% | 28.1% | 28.0% | 33.2% | 33.0% | 33.5% | 36.6% | 38.3% | 39.7% | 41.0% | 41.9% | 42.0% | 41.6% | 41.6% | 42.6% |
| 营业利润（EBIT） | $1.6B | $1.5B | $1.1B | $726M | $1.4B | $3.0B | $2.4B | $1.3B | $1.3B | $1.4B | $1.3B | $1.0B | $910M | $991M | $1.0B | $948M | $979M | $936M | $843M | $777M | $697M |
| 营业利润率% | 11.1% | 10.9% | 8.3% | 6.0% | 12.1% | 23.2% | 17.5% | 11.5% | 11.7% | 13.1% | 13.6% | 11.6% | 15.1% | 17.1% | 18.1% | 17.1% | 19.6% | 19.9% | 18.7% | 19.1% | 19.4% |
| 净利 | $1.0B | $876M | $746M | $418M | $1.3B | $2.4B | $1.6B | $824M | $884M | $1.3B | $732M | $437M | $511M | $574M | $583M | $520M | $558M | $543M | $464M | $477M | $432M |
| 净利润率 % | 6.9% | 6.3% | 5.7% | 3.4% | 10.8% | 18.1% | 11.1% | 7.1% | 7.8% | 12.2% | 7.6% | 5.0% | 8.5% | 9.9% | 10.3% | 9.4% | 11.2% | 11.6% | 10.3% | 11.7% | 12.0% |
| EBITDA | — | $2.0B | $1.8B | $1.3B | $2.0B | $3.7B | $3.3B | $2.1B | $2.1B | $1.8B | $1.8B | $1.6B | $1.2B | $1.2B | $1.3B | $1.2B | $1.2B | $1.1B | $1.0B | $990M | $853M |
| 每股收益（EPS） | $12.19 | $10.46 | $8.84 | $4.77 | $13.96 | $24.38 | $15.88 | $8.35 | $8.61 | $12.21 | $7.02 | $4.34 | $5.92 | $6.25 | $5.99 | $5.11 | $5.30 | $4.98 | $4.10 | $3.93 | $3.24 |
| 已发行股数 (M) | — | 84M | 84M | 88M | 92M | 98M | 98M | 99M | 103M | 104M | 104M | 101M | 86M | 92M | 97M | 102M | 105M | 109M | 113M | 121M | 133M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 LH 交互式查看器。 /companies/us/LH
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms